替比夫定治疗慢性乙型肝炎患者肌酸激酶增高现象分析

肝脏 ›› 2016, Vol. 21 ›› Issue (5): 334-337.

替比夫定治疗慢性乙型肝炎患者肌酸激酶增高现象分析

陈娟, 赵洪雯, 邓玲, 朱研, 张长江, 王小红

400038 重庆第三军医大学西南医院全军感染病研究所, 感染病研究重庆市重点实验室(陈娟,邓玲,朱研,张长江,王小红),肾科(赵洪雯)

收稿日期:2016-02-24 出版日期:2016-05-31 发布日期:2020-07-09
通讯作者: 王小红,Email: wangxhke@126.com

Analysis of telbivudine treatment induced creatine kinase elevation in patients with chronic hepatitis B

CHEN Juan, ZHAO Hong-wen, DENG Ling, ZHU Yan, ZHANG Chang-jiang, WANG Xiao-hong

Institute of Infectious Diseases, Southwest Hospital, The Third Military Medical University, The Chongqing Key Laboratory For Research of Infectious Diseases, Chongqing, 400038, China

Received:2016-02-24 Online:2016-05-31 Published:2020-07-09
Contact: WANG Xiao-hong, Email: wangxhke@126.com

摘要/Abstract

摘要： 目的研究替比夫定(LdT)治疗慢性乙型肝炎(CHB)患者的肌酸激酶(CK)增高情况、增高后的处理及危险因素,评估LdT使用的安全性。方法纳入LdT治疗CHB患者527例,其中联合阿德福韦酯(ADV)91例、LdT单独治疗436例。合并慢性肾脏病(CKD)19例,孕妇58例。观察CK动态变化,肌肉症状,基线及观察结束时病毒、免疫、生化学指标等。结果 321例患者出现CK升高,1~2级增高281例,3~4级增高40例,发生肌炎14例。CK 3~4级增高后换药与不换药组CK下降差异无统计学意义(P=0.16)。男性是CK增高的危险因素( P<0.01),妊娠与CKD为保护因素(P<0.01;P=0.003)。结论 LdT抗病毒治疗过程中出现CK增高是普遍现象(孕妇及合并CKD患者除外),加强监测能提高LdT应用的安全性。

关键词: 慢性乙型肝炎, 替比夫定, 肌酸激酶, 肌炎

Abstract: Objective To investigate clinical features of tebivudine (LdT) induced creatine kinase (CK) elevation and its risk factors in chronic hepatitis B (CHB) patients, and to evaluate safety of LdT.Methods A total of 527 CHB patients were enrolled in this study, and their clinical data was retrospectively analyzed. Among these patients, 91 received LdT plus adefovir dipivoxil (ADV) therapy and 436 received LdT monotherapy, including 19 with CHB concomitant chronic renal disease (CKD) and 58 pregnant women. The CK levels and muscle symptoms were dynamically observed, and virus, immune and biochemical markers both at baseline and the end of therapy were detected, respectively.Results Variable degrees of CK elevation occurred in 321 cases (60.91%), in which 281 cases (53.32%) were in grade 1-2 and 40 cases (7.59%) were in grade 3-4. Additionally, 14 patients (2.65%) were diagnosed as myositis. In patients with CK elevation of grade 3-4, there was no significant difference between the 2 groups (P=0.16). Male was a risk factor for CK elevation with LdT treatment(P<0.001), while pregnance and CKD were protective factors (P<0.001; P=0.003).Conclusion It is quite common of CK elevation in CHB patients treated with LdT, which suggests that strengthening monitor of CK is indispensable for avoiding LdT-induced serious adverse effects. In regard to LdT-induced CK elevation, application of LdT in HBV-infected pregnant women and patients with CHB concomitant CKD might be safe.

Key words: Chronic hepatitis B; Telbivudine; Creatine kinase; Myositis

陈娟, 赵洪雯, 邓玲, 朱研, 张长江, 王小红. 替比夫定治疗慢性乙型肝炎患者肌酸激酶增高现象分析[J]. 肝脏, 2016, 21(5): 334-337.

CHEN Juan, ZHAO Hong-wen, DENG Ling, ZHU Yan, ZHANG Chang-jiang, WANG Xiao-hong. Analysis of telbivudine treatment induced creatine kinase elevation in patients with chronic hepatitis B[J]. Chinese Hepatolgy, 2016, 21(5): 334-337.

参考文献

[1] Gane EJ,Deray G,Liaw YF,et al.Telbivudine improves renal function in patients with chronic hepatitis B.Gastroenterology,2014,146:138-146.
[2] Liaw YF,Gane E,Leung N,et al. GLOBE Study Group.2-Year GLOBE trial results telbivudine is superior to lamivudine in patients withchronic hepatitis B. Gastroenterology,2009,136:486-495.
[3] 胡玉红,易为,刘敏,等.慢性乙型肝炎妇女全孕期应用替比夫定的安全性研究.中华传染病杂志,2014,32:285-288.
[4] Wu QX,Huang HF,Sun XW,et al.Telbivudine prevents vertical transmission of hepatitis b virus from women with high viral loads:a prospective long-term study.Clinl Gastroenterol Hepatol,2015,13:1170-1176.
[5] Fleischer RD,Lok AS.Myopathy and neuropathy associated with nucleos(t)ide analog therapy for hepatitis B.J Hepatol,2009,51:787-791.
[6] 蔡皓东.替比夫定相关性肌酸激酶升高及肌病及其安全应用.药物不良反应杂志,2009,11:254-256.
[7] 朱瑞银,吕世文,藤云龙.替比夫定致横纹肌溶解死亡1例.中国药物警戒,2010,7:309-310.
[8] 中华医学会肝病学分会、感染病学分会.慢性乙型肝炎防治指南(2010年版).肝脏,2011,16:2-16.
[9] Pasternak RC,Smith SC Jr,?Bairey-Merz CN,et al.American Heart Association; National Heart,Lung and Blood Institute.ACC/AHA/NHLBI Clinical Advisory on the Use and Safety of Statins.Circulation,2002,106:1024-1028.
[10] Levey AS,de Jong PE,Coresh J,et al.The definition,classification,and prognosis of chronic kidney disease:a KDIGO Controversies Conference report.Kidney Int,2011,80:17-28.
[11] Xu H,Wang Z,Zheng L,et al.Lamivudine/telbivudine-associated neuromyopathy:neurogenic damage,mitochondrial dysfunction and mitochondrial DNA depletion. J Clin Pathol,2014,67:999-1005.
[12] Fontana RJ. Side effects of long-term oral antiviral therapy for hepatitis B. Hepatology,2009,49:S185-195.
[13] Lee H,Hanes J,Johnson KA.Toxicity of nucleoside analogues used to treat aids and the selectivity of the mitochondrial DNA polymerase. Biochemistry,2003,42:14711-14719.
[14] Chen L,Cheng C,Chen B,et al.Cumulative incidence and risk factors of creatine kinase elevation associated with telbivudine. Eur J Clin Pharmacol,2016,72:235-241.
[15] Hoffman EP,Reeves E,Damsker J,et al.Novel approaches to corticosteroid treatment in Duehenne muscular dystrophy.Phys Med Rehabil Clin N Am,2012,23:821-828.
[16] 任江波,王宇,李红艺,等.替比夫定治疗慢性乙型肝炎期间肌酸激酶升高的观察与分析.中华肝脏病杂志,2012,20:641-643.